Role of isavuconazole in the treatment of invasive fungal infections

References

• Carrillo-MunozAJFinquelievichJTur-TurCCombination antifungal therapy: a strategy for the management of invasive fungal infectionsRev Esp Quimioter201427314115825229370
   PubMed Web of Science ®Google Scholar
• KoushaMTadiRSoubaniAOPulmonary aspergillosis: a clinical reviewEur Respir Rev20112012115617421881144
   PubMedGoogle Scholar
• KoehlerPCornelyOAContemporary Strategies in the Prevention and Management of Fungal InfectionsInfect Dis Clin North Am201630126527526739606
   PubMed Web of Science ®Google Scholar
• PappasPGKauffmanCAAndesDRClinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of AmericaClin Infect Dis2016624e1e5026679628
   PubMed Web of Science ®Google Scholar
• Antibiotic Resistance Threats in the United States2013Centers for Disease Control and Prevention2014 Available from: http://www.cdc.gov/drugresistance/threat-report-2013/Accessed April 22, 2016
   Google Scholar
• LeeflangMMDebets-OssenkoppYJWangJGalactomannan detection for invasive aspergillosis in immunocompromised patientsCochrane Database Syst Rev201512CD00739426716951
   PubMed Web of Science ®Google Scholar
• FarmakiotisDKontoyiannisDPMucormycosesInfect Dis Clin North Am201630114316326897065
   PubMed Web of Science ®Google Scholar
• PetrikkosGSkiadaALortholaryORoilidesEWalshTJKontoyiannisDPEpidemiology and clinical manifestations of mucormycosisClin Infect Dis201254Suppl 1S23S3422247442
   PubMed Web of Science ®Google Scholar
• AllenDWilsonDDrewRPerfectJAzole antifungals: 35 years of invasive fungal infection managementExpert Rev Anti Infect Ther201513678779825843556
   PubMed Web of Science ®Google Scholar
• WalshTJAnaissieEJDenningDWTreatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of AmericaClin Infect Dis200846332736018177225
   PubMed Web of Science ®Google Scholar
• MarrKASchlammHTHerbrechtRCombination antifungal therapy for invasive aspergillosis: a randomized trialAnn Intern Med20151622818925599346
   PubMed Web of Science ®Google Scholar
• Cresemba^® (isavuconazonium sulfate) [package insert]Northbrook, ILAstellas Pharma US, Inc.2015
   Google Scholar
• PfallerMAAntifungal drug resistance: mechanisms, epidemiology, and consequences for treatmentAm J Med20121251 SupplS3S1322196207
   PubMed Web of Science ®Google Scholar
• PfallerMARhombergPRMesserSAJonesRNCastanheiraMIsavuconazole, micafungin, and 8 comparator antifungal agents’ susceptibility profiles for common and uncommon opportunistic fungi collected in 2013: temporal analysis of antifungal drug resistance using CLSI species-specific clinical breakpoints and proposed epidemiological cutoff valuesDiagn Microbiol Infect Dis201582430331325986029
   PubMed Web of Science ®Google Scholar
• PfallerMAMesserSARhombergPRJonesRNCastanheiraMIn vitro activities of isavuconazole and comparator antifungal agents tested against a global collection of opportunistic yeasts and moldsJ Clin Microbiol20135182608261623740727
   PubMed Web of Science ®Google Scholar
• Espinel-IngroffAChowdharyAGonzalezGMMulticenter study of isavuconazole MIC distributions and epidemiological cutoff values for Aspergillus spp. for the CLSI M38-A2 broth microdilution methodAntimicrob Agents Chemother20135783823382823716059
   PubMed Web of Science ®Google Scholar
• ArendrupMCJensenRHMeletiadisJIn Vitro Activity of Isavuconazole and Comparators against Clinical Isolates of the Mucorales OrderAntimicrob Agents Chemother201559127735774226438494
   PubMed Web of Science ®Google Scholar
• SanglardDCosteATActivity of Isavuconazole and Other Azoles against Candida Clinical Isolates and Yeast Model Systems with Known Azole Resistance MechanismsAntimicrob Agents Chemother201560122923826482310
   PubMed Web of Science ®Google Scholar
• ChowdharyAKathuriaSRandhawaHSGaurSNKlaassenCHMeisJFIsolation of multiple-triazole-resistant Aspergillus fumigatus strains carrying the TR/L98H mutations in the cyp51A gene in IndiaJ Antimicrob Chemother201267236236622028200
   PubMed Web of Science ®Google Scholar
• WarnPASharpAParmarAMajithiyaJDenningDWHopeWWPharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal effectAntimicrob Agents Chemother20095383453346119451288
   PubMed Web of Science ®Google Scholar
• SeyedmousaviSBruggemannRJMeisJFMelchersWJVerweijPEMoutonJWPharmacodynamics of isavuconazole in an Aspergillus fumigatus mouse infection modelAntimicrob Agents Chemother20155952855286625753636
   PubMed Web of Science ®Google Scholar
• LepakAJMarchilloKVanHeckerJDiekemaDAndesDRIsavuconazole pharmacodynamic target determination for Candida species in an in vivo murine disseminated candidiasis modelAntimicrob Agents Chemother201357115642564824002092
   PubMed Web of Science ®Google Scholar
• LepakAJMarchilloKVanheckerJAndesDRIsavuconazole (BAL4815) pharmacodynamic target determination in an in vivo murine model of invasive pulmonary aspergillosis against wild-type and cyp51 mutant isolates of Aspergillus fumigatusAntimicrob Agents Chemother201357126284628924100500
   PubMed Web of Science ®Google Scholar
• Schmitt-HoffmannARoosBHeepMSingle-ascending-dose pharmacokinetics and safety of the novel broad-spectrum antifungal triazole BAL4815 after intravenous infusions (50, 100, and 200 milligrams) and oral administrations (100, 200, and 400 milligrams) of its prodrug, BAL8557, in healthy volunteersAntimicrob Agents Chemother200650127928516377698
   PubMed Web of Science ®Google Scholar
• Schmitt-HoffmannARoosBMaaresJMultiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteersAntimicrob Agents Chemother200650128629316377699
   PubMed Web of Science ®Google Scholar
• Schmitt-HoffmannARoosBSpickermannJEffect of mild and moderate liver disease on the pharmacokinetics of isavuconazole after intravenous and oral administration of a single dose of the prodrug BAL8557Antimicrob Agents Chemother200953114885489019667286
   PubMed Web of Science ®Google Scholar
• DesaiASchmitt-HoffmannAHMujaisSTownsendRPopulation Pharmacokinetics of Isavuconazole in Subjects with Mild and Moderate Hepatic ImpairmentAntimicrob Agents Chemother20166053025303126953193
   PubMed Web of Science ®Google Scholar
• ViljoenJAzieNSchmitt-HoffmannAHGhannoumMA phase 2, randomized, double-blind, multicenter trial to evaluate the safety and efficacy of three dosing regimens of isavuconazole compared with fluconazole in patients with uncomplicated esophageal candidiasisAntimicrob Agents Chemother20155931671167925561337
   PubMed Web of Science ®Google Scholar
• Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida InfectionsAstellas Pharma Inc Available from: https://clinicaltrials.gov/ct2/show/NCT00413218?term=NCT00413218&rank=1. NLM identifier: NCT00413218Accessed June 21, 2016
   Google Scholar
• Astellas Pharma US, IncAstellas provides update on phase 3 study evaluating isavuconazole in patients with candidemia and other invasive candidal infections [news release]Northbrook, ILAstellas Pharma US, Inc.2015730 Available from: http://newsroom.astellas.us/2015-07-30-Astellas-Provides-Update-on-Phase-3-Study-Evaluating-Isavuconazole-in-Patients-with-Candidemia-and-Other-Invasive-Candida-InfectionsAccessed March 13, 2016
   Google Scholar
• ReboliACRotsteinCPappasPGAnidulafungin versus fluconazole for invasive candidiasisN Engl J Med2007356242472248217568028
   PubMed Web of Science ®Google Scholar
• MaertensJARaadIIMarrKAIsavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trialLancet20163871002076076926684607
   PubMed Web of Science ®Google Scholar
• SlavinMAThurskyKAIsavuconazole: a role for the newest broad-spectrum triazoleLancet20163871002072672826684608
   PubMed Web of Science ®Google Scholar
• ParkWBKimNHKimKHThe effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trialClin Infect Dis20125581080108722761409
   PubMed Web of Science ®Google Scholar
• MartyFMOstrosky-ZeichnerLCornelyOAIsavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysisLancet Infect Dis Epub201638
   Web of Science ®Google Scholar
• KaraIOTasovaYUguzASahinBMucormycosis-associated fungal infections in patients with haematologic malignanciesInt J Clin Pract200963113413917362481
   PubMed Web of Science ®Google Scholar
• GreenbergRNMullaneKvan BurikJAPosaconazole as salvage therapy for zygomycosisAntimicrob Agents Chemother200650112613316377677
   PubMed Web of Science ®Google Scholar
• van BurikJAHareRSSolomonHFCorradoMLKontoyiannisDPPosaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 casesClin Infect Dis2006427e61e6516511748
   PubMed Web of Science ®Google Scholar
• FalciDRPasqualottoACProfile of isavuconazole and its potential in the treatment of severe invasive fungal infectionsInfect Drug Resist2013616317424187505
   PubMedGoogle Scholar
• PettitNNCarverPLIsavuconazole: A New Option for the Management of Invasive Fungal InfectionsAnn Pharmacother201549782584225940222
   PubMed Web of Science ®Google Scholar
• ShahRRDrug-induced QT interval shortening: potential harbinger of proarrhythmia and regulatory perspectivesBr J Pharmacol20101591586919563537
   PubMed Web of Science ®Google Scholar
• ShahRRBjerregaardPGussakIDrug-induced QT interval shortening: an emerging component in integrated assessment of cardiac safety of drugsJ Electrocardiol201043538638920728017
   PubMed Web of Science ®Google Scholar
• Illnait-ZaragoziMTMartinezGFCurfs-BreukerIFernandezCMBoekhoutTMeisJFIn Vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from CubaAntimicrob Agents Chemother20085241580158218212095
   PubMed Web of Science ®Google Scholar
• KimTJancelTKumarPFreemanAFDrug-drug interaction between isavuconazole and tacrolimus: a case report indicating the need for tacrolimus drug-level monitoringJ Clin Pharm Ther Epub201586
   Web of Science ®Google Scholar
• AshbeeHRBarnesRAJohnsonEMRichardsonMDGortonRHopeWWTherapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical MycologyJ Antimicrob Chemother20146951162117624379304
   PubMed Web of Science ®Google Scholar
• ErvensJGhannoumMGrafBSchwartzSSuccessful isavuconazole salvage therapy in a patient with invasive mucormycosisInfection201442242943224217961
   PubMed Web of Science ®Google Scholar
• PeixotoDGagneLSHammondSPIsavuconazole treatment of a patient with disseminated mucormycosisJ Clin Microbiol20145231016101924403304
   PubMed Web of Science ®Google Scholar
• Diflucan^® (fluconazole) [package insert]New York, NYPfizer2014
   Google Scholar
• Vfend^® (voriconazole) [package insert]New York, NYPfizer2015
   Google Scholar
• SeyedmousaviSVerweijPEMoutonJWIsavuconazole, a broad-spectrum triazole for the treatment of systemic fungal diseasesExpert Rev Anti Infect Ther201513192725488140
   PubMed Web of Science ®Google Scholar
• Noxafil^® (posaconazole) [package insert]Whitehouse Station, NJMerck & Co Inc.2014
   Google Scholar
• NiwaTShiragaTTakagiAEffect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomesBiol Pharm Bull20052891805180816141567
   PubMed Web of Science ®Google Scholar
• BruggemannRJAlffenaarJWBlijlevensNMClinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agentsClin Infect Dis200948101441145819361301
   PubMed Web of Science ®Google Scholar